Seeking Alpha

Merck (MRK) is licensing the experimental skin-patch vaccination developed by Australia's Vaxxas...

Merck (MRK) is licensing the experimental skin-patch vaccination developed by Australia's Vaxxas to further fund research, including human tests, Vaxxas says. The Nanopatch system could protect against disease with only a small percentage of antigens required in needle-based vaccination, and might be cheaply manufactured and even mailed out in case of a flu pandemic.
Comments (1)
  • elsrmp56
    , contributor
    Comments (176) | Send Message
     
    I hate needles.....patch sounds much more civilized and certainly less invasive. May not even have to go to bacteria infested doctor's off ice to get a flu shot.
    I sleep so well at night owning MRK.
    8 Oct 2012, 07:56 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|